Do we still need chemotherapy for AIDS-associated Kaposi’s sarcoma?

References

• Kaposi M. Idiopathisches multiples Pigmentsarkom der haut. Archiv fur Dermatologie und Syphilis 4, 265–273 (1872).
   Google Scholar
• Coburn JG, Morgan JK. Multiple idiopathic hemorrhagic sarcoma of Kaposi. AMA Arch. Derm. 71(5), 618–624 (1955).
   PubMedGoogle Scholar
• Oettle AG. Geographical and racial differences in the frequency of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int. Contra Cancrum 18, 330–363 (1962).
   PubMedGoogle Scholar
• Slavin G, Cameron HM, Forbes C, Mitchell RM. Kaposi’s sarcoma in East African children: a report of 51 cases. J. Pathol. 100(3), 187–199 (1970).
   PubMed Web of Science ®Google Scholar
• Bhagwat GP, Naik KG, Sachdeva R, Bhushan V. Disseminated lymphadenopathic Kaposi’s sarcoma in Zambian children. Med. J. Zambia 14(4), 61–63 (1980).
   PubMedGoogle Scholar
• Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD. Disseminated visceral Kaposi’s sarcoma. Appearance after human renal homograft operation. JAMA 207(8), 1493–1496 (1969).
   PubMed Web of Science ®Google Scholar
• CDC. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men – New York City and California. MMWR Morb. Mortal. Wkly Rep. 30(25), 305–308 (1981).
   PubMedGoogle Scholar
• Gottlieb GJ, Ragaz A, Vogel JV et al. A preliminary communication on extensively disseminated Kaposi’s sarcoma in young homosexual men. Am. J. Dermatopathol. 3(2), 111–114 (1981).
   PubMed Web of Science ®Google Scholar
• Friedman-Kien A, Laubenstein L, Marmor M, Al E. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men-New York and California. MMWR Morb. Mortal. Wkly Rep. 30, 250–254 (1981).
   PubMedGoogle Scholar
• Friedman-Kien AE, Laubenstein LJ, Rubinstein P et al. Disseminated Kaposi’s sarcoma in homosexual men. Ann. Intern. Med. 96(6 Pt 1), 693–700 (1982).
   PubMed Web of Science ®Google Scholar
• Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb. Mortal. Wkly Rep. 36(Suppl. 1), 1S–S15 (1987).
   PubMedGoogle Scholar
• Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22(8), 937–945 (2008).
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl Cancer Inst. 99(12), 962–972 (2007).
   PubMed Web of Science ®Google Scholar
• Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13(Suppl. 2), 1–85 (2012).
   Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Hall HI et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 305(14), 1450–1459 (2011).
   PubMed Web of Science ®Google Scholar
• Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br. J. Cancer 78(11), 1521–1528 (1998).
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur. J. Cancer 37(10), 1188–1201 (2001).
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J. Clin. 61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi’s sarcoma. J. Am. Acad. Dermatol. 22(6 Pt 2), 1237–1250 (1990).
   PubMed Web of Science ®Google Scholar
• Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335(8682), 123–128 (1990).
   PubMed Web of Science ®Google Scholar
• Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13), 1736–1745 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman-Kien AE, Saltzman BR, Cao YZ et al. Kaposi’s sarcoma in HIV-negative homosexual men. Lancet 335(8682), 168–169 (1990).
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Darby S et al. Risk of Kaposi’s sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339(8794), 632–635 (1992).
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266(5192), 1865–1869 (1994).
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332(18), 1186–1191 (1995).
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86(4), 1276–1280 (1995).
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 43(8), 698–704 (2004).
   PubMed Web of Science ®Google Scholar
• Lee FC, Mitsuyasu RT. Chemotherapy of AIDS-related Kaposi’s sarcoma. Hematol. Oncol. Clin. North Am. 10(5), 1051–1068 (1996).
   PubMed Web of Science ®Google Scholar
• Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp. Hematol. Oncol. 1(1), 10 (2012).
   PubMedGoogle Scholar
• Gill PS, Wernz J, Scadden DT et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 14(8), 2353–2364 (1996).
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized Phase III clinical trial. J. Clin. Oncol. 16(7), 2445–2451 (1998).
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. 16(2), 683–691 (1998).
   PubMed Web of Science ®Google Scholar
• Lichterfeld M, Qurishi N, Hoffmann C et al.; German Clinical AIDS Working Group (KAAD). Treatment of HIV-1-associated Kaposi’s sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 33(3), 140–147 (2005).
   PubMed Web of Science ®Google Scholar
• EngelsEA, PfeifferRM, FraumeniJF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17), 1891–1901 (2011).
   PubMed Web of Science ®Google Scholar
• Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J. Natl Cancer Inst. 102(11), 784–792 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobson LP, Yamashita TE, Detels R et al. Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 21(Suppl. 1), S34–S41 (1999).
   PubMed Web of Science ®Google Scholar
• International collaboration on HIV and cancer: highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92(22), 1823–1830 (2000).
   PubMed Web of Science ®Google Scholar
• Portsmouth S, Stebbing J, Gill J et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS 17(11), F17–F22 (2003).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M et al.; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst. 97(6), 425–432 (2005).
   PubMed Web of Science ®Google Scholar
• Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS 13(15), 2105–2111 (1999).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet 367(9521), 1495–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Holkova B, Takeshita K, Cheng DM et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. J. Clin. Oncol. 19(18), 3848–3851 (2001).
   PubMed Web of Science ®Google Scholar
• Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int. J. Cancer 98(6), 916–922 (2002).
   PubMed Web of Science ®Google Scholar
• Powles T, Stebbing J, Bazeos A et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann. Oncol. 20(4), 775–779 (2009).
   PubMed Web of Science ®Google Scholar
• Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J. Acquir. Immune Defic. Syndr. 30(2), 257–258 (2002).
   PubMed Web of Science ®Google Scholar
• Gill J, Bourboulia D, Wilkinson J et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 31(4), 384–390 (2002).
   PubMed Web of Science ®Google Scholar
• Cattelan AM, Calabro ML, Aversa SM et al. Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer 35(13), 1809–1815 (1999).
   PubMed Web of Science ®Google Scholar
• Esdaile B, Davis M, Portsmouth S et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi’s sarcoma. AIDS 16(17), 2344–2347 (2002).
   PubMed Web of Science ®Google Scholar
• Núñez M, Saballs P, Valencia ME et al.; Caelyx/KS Spanish Study Group. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi’s sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials 2(5), 429–437 (2001).
   PubMedGoogle Scholar
• Bower M, Weir J, Francis N et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS 23(13), 1701–1706 (2009).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Gazzard B, Douek DC. Where does HIV live? N. Engl. J. Med. 350(18), 1872–1880 (2004).
   PubMed Web of Science ®Google Scholar
• Carcelain G, Debré P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr. Opin. Immunol. 13(4), 483–488 (2001).
   PubMed Web of Science ®Google Scholar
• Carcelain G, Tubiana R, Samri A et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 75(1), 234–241 (2001).
   PubMed Web of Science ®Google Scholar
• Sgadari C, Barillari G, Toschi E et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. 8(3), 225–232 (2002).
   PubMed Web of Science ®Google Scholar
• Bihl F, Mosam A, Henry LN et al. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS 21(10), 1245–1252 (2007).
   PubMed Web of Science ®Google Scholar
• Bourboulia D, Aldam D, Lagos D et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18(3), 485–493 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkinson J, Cope A, Gill J et al. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J. Virol. 76(6), 2634–2640 (2002).
   PubMed Web of Science ®Google Scholar
• Robey RC, Lagos D, Gratrix F et al. The CD8 and CD4 T-cell response against Kaposi’s sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS ONE 4(6), e5890 (2009).
   PubMedGoogle Scholar
• Zhu FX, Chong JM, Wu L, Yuan Y. Virion proteins of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 79(2), 800–811 (2005).
   PubMed Web of Science ®Google Scholar
• Mosam A, Shaik F, Uldrick TS et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J. Acquir. Immune Defic. Syndr. 60(2), 150–157 (2012).
   PubMed Web of Science ®Google Scholar
• Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 7(9), 1201–1207 (1989).
   PubMed Web of Science ®Google Scholar
• Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 15(9), 3085–3092 (1997).
   PubMed Web of Science ®Google Scholar
• Bower M, Collins S, Cottrill C et al.; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 9(6), 336–388 (2008).
   PubMed Web of Science ®Google Scholar
• Borok M, Fiorillo S, Gudza I et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin. Infect. Dis. 51(3), 342–349 (2010).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G. AIDS. Boosting immunity to HIV – can the virus help? Science 290(5493), 946–949 (2000).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Debre P. Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv. Exp. Med. Biol. 495, 205–212 (2001).
   PubMed Web of Science ®Google Scholar
• Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81(3), 213–227 (2002).
   PubMed Web of Science ®Google Scholar
• Weir A, Wansbrough-Jones M. Mucosal Kaposi’s sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 11(15), 1895–1896 (1997).
   PubMed Web of Science ®Google Scholar
• Connick E, Kane MA, White IE, Ryder J, Campbell TB. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin. Infect. Dis. 39(12), 1852–1855 (2004).
   PubMed Web of Science ®Google Scholar
• Leidner R, Aboulafia D. Flare of AIDS-associated Kaposi’s sarcoma (KS) following HAART: a manifestation of immune reconstitution syndrome. Flare of AIDS-Associated Kaposi’s Sarcoma (KS) Following HAART: A Manifestation of Immune Reconstitution Syndrome. Abstract 16 (2004).
   Google Scholar
• Bower M, Nelson M, Young AM et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J. Clin. Oncol. 23(22), 5224–5228 (2005).
   PubMed Web of Science ®Google Scholar
• Letang E, Almeida JM, Miró JM et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in mozambique: a prospective study. J. Acquir. Immune Defic. Syndr. 53(5), 589–597 (2010).
   PubMed Web of Science ®Google Scholar
• Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin. Infect. Dis. 54(3), 424–433 (2012).
   PubMed Web of Science ®Google Scholar
• Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 19(10), 635–644 (2005).
   PubMed Web of Science ®Google Scholar
• Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J. Periodontol. 79(2), 362–368 (2008).
   PubMed Web of Science ®Google Scholar
• Read PJ, Desai M, Lucas S, Morris S, Kulasegaram R. Immune reconstitution inflammatory syndrome (IRIS)-associated Kaposi sarcoma (KS) in the liver manifesting as acute obstructive hepatitis. HIV Medicine 10, 163 (2009).
   PubMed Web of Science ®Google Scholar
• Pal J, Shrivastav A, Pathak HS, Sarkar DK. Immune reconstitution inflammatory syndrome associated with acquired immunodeficiency syndrome-related gastrointestinal limited Kaposi’s sarcoma presenting as acute intestinal obstruction: a case report. J. Med. Case Rep. 5, 327 (2011).
   PubMedGoogle Scholar
• Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N. Engl. J. Med. 357(13), 1352–1353 (2007).
   PubMedGoogle Scholar
• Krown SE, Lee JY, Dittmer DP; AIDS Malignancy Consortium. More on HIV-associated Kaposi’s sarcoma. N. Engl. J. Med. 358(5), 535–536; author reply 536 (2008).
   PubMed Web of Science ®Google Scholar
• Mani D, Neil N, Israel R, Aboulafia DM. A retrospective analysis of AIDS-associated Kaposi’s sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3). J. Int. Assoc. Physicians AIDS Care (Chic.) 8(5), 279–285 (2009).
   PubMedGoogle Scholar
• Brown LF, Tognazzi K, Dvorak HF, Harrist TJ. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi’s sarcoma and cutaneous angiosarcoma. Am. J. Pathol. 148(4), 1065–1074 (1996).
   PubMed Web of Science ®Google Scholar
• Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl Acad. Sci. USA 94(3), 979–984 (1997).
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Wyvill KM, Kumar P et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J. Clin. Oncol. 30(13), 1476–1483 (2012).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized Phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. 24(9), 1389–1394 (2006).
   PubMed Web of Science ®Google Scholar
• Brinker BT, Krown SE, Lee JY et al. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer 112(5), 1083–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Koon HB, Fingleton B, Lee JY et al. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 56(1), 64–68 (2011).
   PubMed Web of Science ®Google Scholar
• Noy A, Scadden DT, Lee J et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s sarcoma in a Phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J. Clin. Oncol. 23(5), 990–998 (2005).
   PubMed Web of Science ®Google Scholar
• Shimabukuro KA, Reid EG. AMC 070: a Phase I/II study of lenalidomide in patients with AIDS-associated Kaposi sarcomas. J. Clin. Oncol. 29(15 Suppl. 1), Abstract TPS246 (2011).
   Google Scholar
• Koon HB, Bubley GJ, Pantanowitz L et al. Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 23(5), 982–989 (2005).
   PubMed Web of Science ®Google Scholar
• Ardavanis A, Doufexis D, Kountourakis P, Rigatos G. A Kaposi’s sarcoma complete clinical response after sorafenib administration. Ann. Oncol. 19(9), 1658–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Vart RJ, Nikitenko LL, Lagos D et al. Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 67(9), 4042–4051 (2007).
   PubMed Web of Science ®Google Scholar
• Krown SE, Roy D, Lee JY et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J. Acquir. Immune Defic. Syndr. 59(5), 447–454 (2012).
   PubMed Web of Science ®Google Scholar
• Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 13(1), 27–46 (2008).
   PubMed Web of Science ®Google Scholar